Lakefront Biotherapeutics (LKFT) vs Pharvaris N.V. (PHVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pharvaris N.V. (PHVS) has outperformed Lakefront Biotherapeutics (LKFT) over the past year, gaining 26.0% versus a gain of 8.6%. Over five years, PHVS leads with a +131.3% price change compared with -31.8% for LKFT. Pharvaris N.V. is the larger company by market cap ($2.21 billion vs $2.18 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LKFT | PHVS |
|---|---|---|
| Share price | $33.31 | $31.28 |
| Market cap | $2.18B | $2.21B |
| 1-day change | -0.24% | -1.20% |
| YTD return | +1.87% | +12.72% |
| 1-year return | +8.64% | +25.98% |
| 5-year return | -31.80% | +131.28% |
| P/E ratio (TTM) | 2.39 | — |
| EPS (TTM) | $13.94 | $-3.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-25.99M |
| 52-week high | $36.24 | $43.25 |
| 52-week low | $25.68 | $23.15 |
| Distance from 52-week high | -8.08% | -27.68% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -7.39% | +86.29% |
| Average volume | 280.49K | 756.20K |
| Shares outstanding | 65.48M | 70.79M |
| Employees | 196 | 168 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHVS has outperformed LKFT by 17.3 percentage points over the past year.
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
LKFT vs PHVS FAQ
Which is bigger, Lakefront Biotherapeutics or Pharvaris N.V.?
Pharvaris N.V. (PHVS) is larger, with a market capitalization of $2.21B compared with $2.18B for Lakefront Biotherapeutics (LKFT).
Which stock has performed better over the past year, LKFT or PHVS?
PHVS returned +25.98% over the past 12 months, compared with +8.64% for LKFT (price return, excluding dividends). Past performance does not predict future results.
Are Lakefront Biotherapeutics and Pharvaris N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.